Motta Mario, Chirico Gaetano, Rebaioli Chiara Biasini, Faden David, Lojacono Andrea, Allegri Flavio, Migliori Claudio, Tincani Angela
Division of Neonatology and NICU, Spedali Civili, Brescia, Italy.
Am J Perinatol. 2006 May;23(4):247-51. doi: 10.1055/s-2006-939533. Epub 2006 Apr 19.
Infants born from mothers with antiphospholipid antibody (aPL) -positive autoimmune disease were prospectively evaluated for anticardiolipin and anti-beta2 glycoprotein I antibodies (group 1) and for growth and neurological development. The results were compared with those obtained from two age-matched control groups (group 2 and 3). All infants were negative for anticardiolipin at 12 months of life, whereas 14 (63.6%), eight (33.3%), and 10 (55.5%) of infants from group 1, 2, and 3, respectively, were positive for anti-beta2 glycoprotein I. At follow-up, all infants had normal growth and neurological development. No thrombotic complication was observed. The negativity of anticardiolipin in all infants at 12 months suggests that anticardiolipin detection is the best assay to evaluate the disappearance of maternal aPL and to estimate the potential risk of thrombosis associated with these antibodies. The high rate of anti-beta2 glycoprotein I positivity in all three groups of infants may indicate that the synthesis of this antibody is stimulated by aspecific factors.
对患有抗磷脂抗体（aPL）阳性自身免疫性疾病的母亲所生婴儿进行前瞻性评估，检测其抗心磷脂抗体和抗β2糖蛋白I抗体（第1组），并评估其生长和神经发育情况。将结果与两个年龄匹配的对照组（第2组和第3组）的结果进行比较。所有婴儿在12个月大时抗心磷脂抗体均为阴性，而第1组、第2组和第3组分别有14名（63.6%）、8名（33.3%）和10名（55.5%）婴儿抗β2糖蛋白I呈阳性。随访时，所有婴儿生长和神经发育均正常。未观察到血栓形成并发症。所有婴儿在12个月时抗心磷脂抗体呈阴性，这表明检测抗心磷脂抗体是评估母体aPL消失情况以及估计与这些抗体相关的潜在血栓形成风险的最佳检测方法。三组婴儿中抗β2糖蛋白I阳性率较高，这可能表明该抗体的合成受到非特异性因素的刺激。
